Skip to main content
Menu
US

HTRF Human Total IKZF3 Detection Kit, 500 Assay Points

This HTRF kit enables the cell-based quantitative detection of Total IKZF3.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Cell Signaling
Sample Volume 16 µL

This HTRF kit enables the cell-based quantitative detection of Total IKZF3.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 500 Assay Points
Part #:
64IKZF3TPEG
List Price
USD 2,147.00
Unit Size: 10,000 Assay Points
Part #:
64IKZF3TPEH
List Price
USD 12,490.00

Overview

The Ikaros zinc-finger (IKZF) family of transcription factors are essential regulators of lymphopoiesis. IKZF1 (Ikaros) and IKZF3 (Aiolos) function as both transcriptional repressors and activators during T and B cell differentiation, as well as in the function of mature cells. Ikaros family proteins partner with multiple complexes, including NuRD, PRC2, and transcription elongation factors. Through these associations, they can modulate gene expression profiles and the chromatin state. the overexpression of these proteins has been linked to sustaining cancer cell proliferation and survival, such as malignant plasma cells and multiple myeloma.

Among the therapeutic strategies investigated to fight cancers, the use of IMIDs (immunomodulatory imide drugs ) and their derivatives, termed CELMoDs (Cereblon E3 Ligase Modulatory Drugs), has become a popular strategy. By binding to CRBN, these compounds induce the ubiquitination of targeted proteins and promote their subsequent degradation. CELMoDs targeting IKZF1 and IKZF3 have shown promising anti-tumor activity in multiple myeloma cell models.

Specifications

Application
Cell Signaling
Brand
HTRF
Detection Modality
HTRF
Molecular Modification
Total
Product Group
Kit
Sample Volume
16 µL
Shipping Conditions
Shipped in Dry Ice
Target Class
Phosphoproteins
Technology
TR-FRET
Unit Size
500 Assay Points

How it works

Total IKZF3 assay principle

The HTRF Total IKZF3 assay quantifies the expression level of IKZF3 in a cell lysate. Unlike Western Blot, the assay is entirely plate-based, and does not require gels, electrophoresis, or transfer. The Total IKZF3 assay uses two labeled antibodies, one coupled to a donor fluorophore and the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In presence of IKZF3 in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein’s expression under a no-wash assay format.

Principle of the HTRF Total IKZF3 assay
Total IKZF3 two-plate assay protocol

The 2-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a 384-well low volume detection plate before the addition of the Total IKZF3 HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

Two-plate protocol of the HTRF Total IKZF3 assay
Total IKZF3 one-plate assay protocol

Detection of Total IKZF3 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS-designed protocol enables miniaturization while maintaining robust HTRF quality.

One-plate protocol of the HTRF Total IKZF3 assay

 

Assay validation

HTRF Total IKZF3 modulation using IMID and CELMoDs on Ramos cells

Ramos cells were seeded in 96-well culture plate (50,000 cells/30µL well) and treated with increasing concentrations of the IMID Lenalidomide or the CELMoDs Iberdomide and Avadomide, described as inducers of IKZF1 and IKZF3 degradation.

After overnight incubation, cells were lysed with 10 µL of supplemented lysis buffer #4 (4X) for 30 min at RT under gentle shaking. Next, 16 µL of lysate were transferred into a 384-well low volume white microplate, and 4 µL of the HTRF Total IKZF3 detection antibodies were added. An additional 4 µL of lysate (supplemented with 12 µL diluent #8) were also transferred into the microplate to check the alpha-tubulin level with the alpha-tubulin housekeeping cellular Kit (64ATUBPET/G/H). HTRF signals were recorded after an overnight incubation.

The three compounds triggered an IKZF3 dose-dependent decrease in protein expression levels, whereas the alpha-tubulin expression level as well as ATP levels remained stable as expected.

Our results indicate that Iberdomide and Avadomide induce IKZF3 degradation with higher potency (DC50* 6nM and 29nM, respectively) and efficacy (88% and 92% degradation rate, respectively) compared to Lenalidomide (DC50* 76nM and degradation rate 74%), as described in the literature by Fuchs et al. (Blood Reviews, 2023).

*DC50  corresponds to the concentration of the degrader at which 50% of the targeted protein is degraded.

Total IKZF3 on Ramos cells treated with IMID and CELMoDs
Total IKZF3 on Ramos cells treated with IMID and CELMoDs
Total IKZF3 on Ramos cells treated with IMID and CELMoDs

Molecular glue degrader 

Protein target

E3 Ligase

DC50 (nM)

Degradation rate

Lenalidomide (IMID)

IKZF3

CRBN

76

74%

Iberdomide (CELMoD)

IKZF3

6

88%

Avadomide (CELMoD)

IKZF3

29

92%

Total IKZF3 modulation using CELMoDs is mediated by the ubiquitin-proteasome system

Ramos cells were seeded in 96-well culture plate (50,000 cells/30µL well) and treated with increasing concentrations of the CELMoD  Avadomide for 4h or 24h. The proteasome inhibitor epoxomicin (1µM) was added or not 1h prior to the addition of Avadomide .

After treatment, cells were lysed with 10 µl of supplemented lysis buffer #4 (4X) for 30 min at RT under gentle shaking. Next, 16 µL of lysate were transferred into a 384-well low volume white microplate, and 4 µL of the HTRF Total IKZF3 detection antibodies were added. An additional 4 µL of lysate (supplemented with 12 µL diluent #8) were also transferred into the microplate to check the alpha-tubulin level with the alpha-tubulin housekeeping Cellular Kit (64ATUBPET/G/H). HTRF signals were recorded after an overnight incubation.

The CELMoD Avadomide induced a dose-dependent decrease in IKZF3 protein levels, with DC50* of 56 nM and 29 nM after 4h and 24h respectively. Furthermore, Avadomide-induced IKZF3 degradation was prevented in the presence of epoxomicin, a proteasome activity inhibitor. This result unambiguously demonstrates that Avadomide-induced IKZF3 degradation is mediated by the ubiquitin proteasome system. Similar data were obtained when treating cells with Lenalidomide (IMID) or Iberdomide (CELMoD) (data not shown).

* DC50  corresponds to the concentration of the degrader at which 50% of the targeted protein is degraded.

Total IKZF3 on Ramos cells treated with IMID and CELMoDs
HTRF Total IKZF1 versus IKZF3 modulation using IMID and CELMoDs on Ramos cells

Ramos cells were seeded in 96-well culture plate (50,000 cells/30µL well) and treated with increasing concentrations of the IMID Lenalidomide or the CELMoDs Iberdomide and Avadomide, described as inducing IKZF1 and IKZF3 degradation.

After overnight incubation, cells were lysed with 10 µL of supplemented lysis buffer #4 (4X) for 30 min at RT under gentle shaking. Next, 16 µL of lysate were transferred into a 384-well low volume white microplate, and 4 µL of the Total IKZF1 or Total IKZF3 detection antibodies were added. HTRF signals were recorded after an overnight incubation.

The three compounds triggered an IKZF1 and IKZF3 dose-dependent decrease in protein expression, whereas the alpha-tubulin expression level as well as ATP levels remained stable as expected (data not shown). Our results indicate that Lenalidomide, Iberdomide, and Avadomide are equally potent in inducing either IKZF1 or IKZF3 degradation.

Total IKZF3 on Ramos cells treated with IMID and CELMoDs
Total IKZF3 on Ramos cells treated with IMID and CELMoDs
Total IKZF3 on Ramos cells treated with IMID and CELMoDs

Molecular glue degrader 

E3 Ligase

Protein target

DC50 (nM)

Degradation rate

Lenalidomide (IMID)

CRBN

IKZF1

110

61%

IKZF3

76

74%

Iberdomide (CELMoD)

IKZF1

10

81%

IKZF3

6

88%

Avadomide (CELMoD)

IKZF1

64

88%

IKZF3

29

92%

Specificity and selectivity of HTRF Total IKZF3 assay

HAP1 cells were transfected with human IKZF3, human IKZF1 plasmids in a T175 flask and incubated for 24h. After medium removal, cells were lysed with 3 mL of supplemented lysis buffer #4 (1X) for 30 min at RT under gentle shaking.

The IKZF3 expression levels were assessed with the HTRF Total IKZF3 kit. Briefly, 16 µL of cell lysate were transferred into a low volume white microplate, followed by 4 µL of premixed HTRF detection reagents. The HTRF signal was recorded after an overnight incubation at RT.

The HTRF Total IKZF3 assay efficiently detected IKZF3 in the IKZF3 transfected HAP1 cells compared to the WT HAP1 cells. No signal was detected in IKZF1 transfected cells, demonstrating the specificity and selectivity of the kit.

Specificity of Total IKZF3 assay
Validation on various Human cell lines

The suspension cell lines MOLT-4 (T lymphoblast), Ramos (B lymphocyte), and Raji (B lymphoblastoid) were dispensed into a 96-well plate, and lysed with 10 µL of supplemented lysis buffer #4 (4X) for 30 min at RT under gentle shaking (performed according to the suspension cell protocol).

The IKZF3 expression level was assessed with the HTRF Total IKZF3 kit. Briefly, 16 µL of cell lysate were transferred into a low volume white microplate, followed by 4 µL of premixed HTRF detection reagents. The HTRF signal was recorded after an overnight incubation at RT. The dotted line corresponds to the non-specific HTRF signal. Note that the cell density was optimized beforehand to ensure HTRF detection within the dynamic range of the kit (data are shown for 100,000 cells/well)

The HTRF Total IKZF3 assay efficiently detected endogenous IKZF3 in various cellular models expressing different levels of the protein.

Specificity of Total IKZF3 assay using various human and murine cell lines
 Comparison between HTRF and Western Blot sensitivity for Total IKZF3

Ramos cells were cultured in a T175 flask in complete medium at 37°C, 5% CO2. After medium removal, the cells were lysed with 3 mL of supplemented lysis buffer #4 (1X) for 30 min at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer #4 (1X), and 16µL of each dilution were transferred into a 384-well small volume microplate before the addition of 4µL of HTRF Total IKZF3 detection antibodies. HTRF signals were recorded after an overnight incubation.

Equal amounts of lysates were loaded into a gel for a side-by-side comparison between HTRF and Western Blot.

In these conditions, the HTRF Total IKZF3 assay is 16-fold more sensitive than the Western Blot technique.

HTRF Total IKZF3 assay compared to Western Blot

 

Simplified pathway

IKZF3 Signaling Pathway

Ikaros zinc finger transcription factors are important regulators of the gene programs underlying the development of hematopoietic cell lineages. They recruit different co-factors and interact with target gene loci or chromatin-remodeling complexes. Ikaros mediate different transcriptional outcomes by acting as transcriptional repressors or activators based on cell type.

Total IKZF3 Signaling Pathway

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Brochure Icon
Brochure
HTRF assays and reagents catalog

Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...

Brochure Icon
Brochure
Species compatibility for HTRF, AlphaLISA SureFire Ultra and Alpha SureFire Ultra Multiplex assays

This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...

SDS, COAs, Manuals and more

Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.

Safety data sheet
+ Show more
Certificate of analysis
+ Show more
IFUs, Manuals & more
Scroll Icon